The Traveler’s Diarrhea Therapeutics market is expected to exceed more than US$ 9.70 Billion by 2028 at a CAGR of 7.1% in the given forecast period.
Incensing number of frequent flyers and flourishing tourism business in developing region is anticipated to drive the market for traveler’s diarrhea treatment market over the study period. The increasing awareness among the end user for advanced traveler’s diarrhea treatment is anticipated to propel the market growth for traveler’s diarrhea treatment market. The ease and convenience in obtaining drugs and availability of over the counter medications is anticipated to offer lucrative growth opportunities for the traveler’s diarrhea treatment market. The advantage offered by vaccines used in cholera in treatment of traveler’s diarrhea is anticipated to impel the market growth for traveler’s diarrhea treatment. However, side effects associated with the antimicrobial drugs and associated depletion of the digestive flora is anticipated to restrain the market for traveler’s diarrhea treatment.
Traveler’s diarrhea (TD) is a stomach and intestinal infection. TD is defined as the passage of unformed stool (one or more by some definitions, three or more by others) while traveling. It may be accompanied by abdominal cramps, nausea, fever, and bloating. Occasionally bloody diarrhea may occur. Most travelers recover within four days with little or no treatment. About 10% of people may have symptoms for a week.
Traveler’s diarrhea is the leading cause of illness among international travelers to developing countries. Enterotoxigenic Escherichia coli (ETEC) bacteria are the primary cause of this disease. Among the estimated 65 million travelers from industrialized countries to high-risk areas in the developing world, as many as 50% may experience at least one TD episode during their journey.
The global Traveler’s Diarrhea Therapeutics market is segregated on the basis of Application as Adult Traveler’s Diarrhea and Children Traveler’s Diarrhea. Based on Type the global Traveler’s Diarrhea Therapeutics market is segmented in Immunization, Non-antibiotic Agents, Antibiotics, Anti-Motility Agents, and Other.
The global Traveler’s Diarrhea Therapeutics market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Traveler’s Diarrhea Therapeutics market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.
Competitive Rivalry
Salix Pharmaceuticals, P&G, Johnson & Johnson, Otsuka Pharma, Valneva, Shanghai United Cell, PaxVax, Livzon, Immuron and others are among the major players in the global Traveler’s Diarrhea Therapeutics market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.
The Traveler’s Diarrhea Therapeutics Market has been segmented as below:
Traveler’s Diarrhea Therapeutics Market, By Application
Traveler’s Diarrhea Therapeutics Market, By Type
Traveler’s Diarrhea Therapeutics Market, By Region
Traveler’s Diarrhea Therapeutics Market, By Company
The report covers:
Report Scope:
The global Traveler’s Diarrhea Therapeutics market report scope includes detailed study covering underlying factors influencing the industry trends.
The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.
The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Traveler’s Diarrhea Therapeutics market share. Major industry players with significant revenue share include Salix Pharmaceuticals, P&G, Johnson & Johnson, Otsuka Pharma, Valneva, Shanghai United Cell, PaxVax, Livzon, Immuron, and others.
Reasons to Buy this Report:
Customization
Customized report as per the requirement can be offered with appropriate recommendations
Below are our new reports:
Sterile Tissue Adhesive Market
1. Introduction
1.1 Key Insights
1.2 Report Overview
1.3 Markets Covered
1.4 Stakeholders
2. Research Methodology
2.1 Research Scope
2.2 Market Research Process
2.3 Research Data Analysis
2.4.1 Secondary Research
2.4.2 Primary Research
2.4.3 Models for Estimation
2.5 Market Size Estimation
2.5.1 Bottom-Up Approach – Segmental Market Analysis
2.5.2 Top-Down Approach – Parent Market Analysis
3. Executive Summary
4. Market Overview
4.1 Introduction
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Challenges
4.2 Porter’s Five Force Analysis
5. Traveler’s Diarrhea Therapeutics Market, By Application
5.1 Introduction
5.2 Adult Traveler’s Diarrhea
5.2.1 Market Overview
5.2.2 Market Size and Forecast
5.3 Children Traveler’s Diarrhea
5.3.1 Market Overview
5.3.2 Market Size and Forecast
6. Traveler’s Diarrhea Therapeutics Market, By Type
6.1 Introduction
6.2 Immunization
6.2.1 Market Overview
6.2.2 Market Size and Forecast
6.3 Non-antibiotic Agents
6.3.1 Market Overview
6.3.2 Market Size and Forecast
6.4 Antibiotics
6.4.1 Market Overview
6.4.2 Market Size and Forecast
6.5 Anti-Motility Agents
6.5.1 Market Overview
6.5.2 Market Size and Forecast
6.6 Other
6.6.1 Market Overview
6.6.2 Market Size and Forecast
7. Traveler’s Diarrhea Therapeutics Market, By Geography
7.1 Introduction
7.2 North America
7.2.1 North America Traveler’s Diarrhea Therapeutics, By Application
7.2.2 North America Traveler’s Diarrhea Therapeutics, By Type
7.3 Europe
7.3.1 Europe Traveler’s Diarrhea Therapeutics, By Application
7.3.2 Europe Traveler’s Diarrhea Therapeutics, By Type
7.4 Asia-Pacific
7.4.1 Asia-Pacific Traveler’s Diarrhea Therapeutics, By Application
7.4.2 Asia-Pacific Traveler’s Diarrhea Therapeutics, By Type
7.5 Rest of the World
7.5.1 Rest of the World Traveler’s Diarrhea Therapeutics, By Application
7.5.2 Rest of the World Traveler’s Diarrhea Therapeutics, By Type
8. Competitive Insights
8.1 Key Insights
8.2 Company Market Share Analysis
8.3 Strategic Outlook
8.3.1 Mergers & Acquisitions
8.3.2 New Product Development
8.3.3 Portfolio/Production Capacity Expansions
8.3.4 Joint Ventures, Collaborations, Partnerships & Agreements
8.3.5 Others
9. Company Profiles
9.1 Salix Pharmaceuticals
9.1.1 Company Overview
9.1.2 Product/Service Landscape
9.1.3 Financial Overview
9.1.4 Recent Developments
9.2 P&G
9.2.1 Company Overview
9.2.2 Product/Service Landscape
9.2.3 Financial Overview
9.2.4 Recent Developments
9.3 Johnson & Johnson
9.3.1 Company Overview
9.3.2 Product/Service Landscape
9.3.3 Financial Overview
9.3.4 Recent Developments
9.4 Otsuka Pharma
9.4.1 Company Overview
9.4.2 Product/Service Landscape
9.4.3 Financial Overview
9.4.4 Recent Developments
9.5 Valneva
9.5.1 Company Overview
9.5.2 Product/Service Landscape
9.5.3 Financial Overview
9.5.4 Recent Developments
9.6 Shanghai United Cell
9.6.1 Company Overview
9.6.2 Product/Service Landscape
9.6.3 Financial Overview
9.6.4 Recent Developments
9.7 PaxVax
9.7.1 Company Overview
9.7.2 Product/Service Landscape
9.7.3 Financial Overview
9.7.4 Recent Developments
9.8 Livzon
9.8.1 Company Overview
9.8.2 Product/Service Landscape
9.8.3 Financial Overview
9.8.4 Recent Developments
9.9 Immuron
9.9.1 Company Overview
9.9.2 Product/Service Landscape
9.9.3 Financial Overview
9.9.4 Recent Developments
The Traveler’s Diarrhea Therapeutics Market has been segmented as below:
Traveler’s Diarrhea Therapeutics Market, By Application
Traveler’s Diarrhea Therapeutics Market, By Type
Traveler’s Diarrhea Therapeutics Market, By Region
Traveler’s Diarrhea Therapeutics Market, By Company
